Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Foamix Pharmaceuticals (FOMX) Share Price
Media coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 46.8166492250892 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
FOMX has been the subject of a number of recent analyst reports. HC Wainwright initiated coverage on shares of Foamix Pharmaceuticals in a research note on Thursday, August 24th. They issued a “buy” rating and a $12.00 target price for the company. Zacks Investment Research cut shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd.
Shares of Foamix Pharmaceuticals (NASDAQ FOMX) traded down $0.02 during midday trading on Monday, reaching $5.67. 37,200 shares of the company’s stock traded hands, compared to its average volume of 160,594. Foamix Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $11.27.
Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.90 million. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. The business’s revenue was down 64.6% on a year-over-year basis. equities research analysts predict that Foamix Pharmaceuticals will post -1.34 earnings per share for the current year.
WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-foamix-pharmaceuticals-fomx-share-price/1743584.html.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.